APPY1: Pivotal trial data

Top-line data from the U.S. pivotal CP-12 trial in 1,887 patients showed that Venaxis' APPY1 Test had an NPV of 97.3% for identifying patients at low risk for appendicitis. APPY1 Test also had 96.9% s...